United Kingdom

GPs use cognitive screening tools like the General Practitioner Assessment of Cognition (GPCOG), 6-item Cognitive Impairment Test (6CIT), or Mini-Cog to determine if a referral to a specialist is needed. If dementia is still suspected, the person is referred to a memory service for more comprehensive neuropsychological testing with instruments like the Addenbrooke’s Cognitive Examination (ACE-III) or the Montreal Cognitive Assessment (MoCA).

As of September 2025, the UK does not have a national screening programme for dementia in the general asymptomatic population, a policy maintained by the UK National Screening Committee. This is based on the lack of validated pre-symptomatic tests and concerns about potential harm versus benefit. However, in June 2025, The UK National Screening Committee opened a consultation to re-examine evidence relating to population screening for dementia. It is worth noting that a targeted screening policy is occasionally applied to high-risk groups, such as older adults admitted to hospital.
.

Brain scans such as CT and MRI are available and used in the UK as part of the diagnostic process for Alzheimer’s disease. For MRI scans through the NHS, waiting times can be significant and highly variable depending on local backlogs. Recent Memory Assessment Services (MAS) audit data for England highlights this disparity in dementia care; the mean wait time from when a brain scan is requested to when it is performed ranges drastically from 5 to 132 days, with a national average of 42 days. The use of advanced functional imaging like SPECT and PET is not routine and is recommended only for complex cases where a dementia diagnosis remains uncertain after initial assessments. PET scans are “uncommon in the UK” for routine diagnosis because they are expensive and many NHS trusts lack the capacity to provide them. England has the lowest number of PET and MRI scanners and the second-lowest of AD specialists per capita among the G7 countries. To address this shortfall in England, the NHS has national contracts with several private companies which provide PET-CT services. A patient’s access to a PET scan in England is often dependent on their geographical location and local service agreements. In Scotland, access to FDG-PET for dementia is described as “extremely limited”, with the existing service already stretched by oncology demands. SPECT scans are more widely available and are the more commonly used functional imaging technique for dementia diagnosis in Scotland.

NHS genetic testing for Alzheimer’s disease is not routine, and eligibility requires a strong family history and a young age of symptom onset (typically under 65). The process is managed by specialist NHS Clinical Genetics Services with mandatory genetic counselling. Testing for the APOE gene, a common risk factor for the more prevalent late-onset AD, is not recommended for clinical diagnosis, and the use of direct-to-consumer kits is discouraged by Alzheimer’s Society.

Analysis of cerebrospinal fluid (CSF) is recommended by NICE guidelines for diagnostically uncertain cases. However, its use is not widespread in the NHS.

The UK’s Blood Biomarker Challenge, a major research initiative, is currently working to validate blood-based biomarker tests for NHS use. This effort is driven by the urgent need for a scalable diagnostic tool to identify eligible patients for new disease-modifying treatments.

Memory clinics in the UK are usually located within hospital units, but access to these specialist services is highly inconsistent. This creates a “postcode lottery” where the timeliness and quality of care vary significantly based on location, with rural and deprived areas often facing the greatest hurdles. The extent of this inequality is clearly reflected in regional dementia diagnosis rates; according to NHS England primary care data from January 2026, there is a 20.3 percentage point gap between the highest and lowest performing Integrated Care Boards.

The provision of home and day care is a mixed landscape; a large private market offers extensive at-home care services, though their coverage is not uniform nationwide. Day centres and community support groups are run by local councils and various charities. This erosion of public and voluntary sector provision creates significant gaps in the support network, leaving many families without access to affordable respite and socialisation opportunities.

Palliative and end-of-life care facilities for people with Alzheimer’s disease are available across four main settings. Many people receive care at home, supported by a coordinated team of community palliative care nurses, district nurses, and their GP, with social services providing necessary equipment. For those in residential or nursing homes, end-of-life care is often provided in place, with staff working alongside local hospice outreach teams and community nurses; homes accredited under the Gold Standards Framework have staff with specialised training in this area. Finally, hospices offer a dedicated and specialised facility for this type of care. A growing number of hospices are developing specialised dementia services; for example, some employ their own Admiral Nurses, create dementia-friendly inpatient rooms, and offer specific programmes to provide sensory and emotional support. Many hospices also serve as a base for community palliative care teams who can visit people at home. It is worth noting that admiral nurses are also used more widely, not only in palliative and end-of-life care scenarios.

Established Alzheimer’s disease medications (Donepezil, Rivastigmine, Galantamine, and Memantine) are funded by the NHS.

Although the NHS provides free healthcare, most of the support needed for dementia (help with washing, dressing, eating, supervision) is classified as social care. Social Care is provided by local councils and is not free. It is subject to a strict financial assessment, or “means test”. Under the means test in England, if an individual has capital (savings, assets, and potentially their home) of more than £23,250, they are considered a “self-funder” and must pay for 100% of their care costs. Because of this threshold, a majority of homeowners are required to pay for their own care. The government, via the local council, only provides financial support for those with assets below this limit.

NHS Continuing Healthcare (CHC) is a package of ongoing care arranged and funded solely by the NHS for adults living with significant and complex health needs. If an individual is deemed eligible for CHC, all of their care costs—including health, personal care, and accommodation if in a care home—are covered by the NHS, free of charge. However, CHC might be difficult to obtain, particularly for people living with dementia. A diagnosis of dementia does not automatically qualify a person for CHC funding. Eligibility is based on having a “primary health need”, which is determined by the complexity, intensity, and unpredictability of an individual’s health requirements.

The financial costs of Alzheimer’s disease care are overwhelmingly borne by the person living with dementia and their family. An estimated 63% of the total cost of dementia in the UK is paid for by individuals and their families. One study report that in England AD dementia subpopulations incur 1.32 to 1.66 times the average annual healthcare cost, which is £4,548. Additionally, for the 48% of patients who used social care services, the healthcare costs amounted to £5,433 per person per year. Further, an estimated 112,540 people in England have had to leave their jobs to care for someone living with dementia, and many more have reduced their working hours, resulting in a direct loss of income and pension contributions for the family.

The primary state benefit for carers is the Carer’s Allowance (or the Carer Support Payment in Scotland), a weekly payment (£83.30) for those who care for someone at least 35 hours a week and earn below a certain threshold. To qualify, the person living with Alzheimer’s disease must receive a specific disability benefit, such as Attendance Allowance or Personal Independence Payment.

Other government support includes the Carer Element within Universal Credit for low-income working-age carers (£201.68 per month), the Carer Addition to Pension Credit for those of state pension age (£46.40 per week), and Carer’s Credit, which protects a carer’s future State Pension entitlement. In Wales, Carers Support Fund offers grants for a wide range of needs including fuel costs and IT equipment.

The single most important scheme is the statutory Carer’s Assessment, a legal right for any unpaid carer to have their needs evaluated by their local council (or Health and Social Care Trust in Northern Ireland). This assessment is the gateway to a range of tailored support, which can include funding for respite care—providing the carer with a crucial break through day centres, short stays in a care home, or in-home help.

Beyond the state, Dementia UK provides specialist Admiral Nurses who offer free, one-to-one expert guidance to families on managing the complexities of dementia. The Alzheimer’s Society runs local services like Memory Cafes and Singing for the Brain groups, which provide stimulation for the person living with dementia and peer support for the carer.

Initially, the Living Well with Dementia strategy, launched in 2009, laid the groundwork for a more person-centred approach to care. Its primary objectives were to ensure early diagnosis and intervention, improve the quality of care in various settings (from hospitals to care homes) and provide better information and support for both individuals living with dementia and their carers. This foundational strategy sought to establish a baseline of good practice across the country.

National dementia planning in the UK has been subject to significant delays and shifting political priorities. A much-anticipated, dedicated 10-year dementia strategy was scrapped by the previous government, which instead intended to incorporate dementia into a broader Major Conditions Strategy. This proposed strategy grouped dementia alongside cancers, cardiovascular diseases, chronic respiratory diseases, mental ill health, and musculoskeletal disorders. Although a call for evidence for this integrated plan concluded in 2023, it was ultimately shelved without being launched, leaving a policy gap until the subsequent introduction of the 10-Year Health Plan.

In July 2025, the Government published its long-awaited 10 Year Health Plan for England. The plan’s explicit commitments to dementia focus primarily on prevention strategies, the establishment of a Modern Service Framework for Frailty and Dementia, and a firm recommitment to the Dame Barbara Windsor Dementia Goals Programme. Furthermore, while not explicitly framed around dementia, the plan’s broader systemic ambitions — such as shifting care into the community through Neighbourhood Health Services, increasing primary care funding, and expanding the use of the NHS App — have the potential to indirectly improve the wider diagnostic pathway.

In Northern Ireland, the Regional Dementia Care Pathway provides a fully integrated, primary care-led delivery model to operationalise the region’s broader strategy. It is designed to assist practitioners in delivering high-quality, consistent care at every stage of the condition, from the initial memory assessment through to end-of-life support.

In Scotland, the 10-year strategy Dementia in Scotland: Everyone’s Story was published in May 2023. It takes a strong human-rights-based approach, focusing on tackling systemic stigma, delivering equitable access to post-diagnostic support, and ensuring that people living with dementia and their families are actively included in their communities.

In Wales, a draft Dementia Strategy for 2026 to 2036 is currently out for public consultation until April 2026. Replacing the 2018 Action Plan, this 10-year strategy was co-produced with people who have lived experience and focuses on delivering person-centred care, reducing societal stigma, and providing better practical support for unpaid carers.

There is no new national dementia strategy for the UK on the immediate horizon. Rather than pursuing a standalone national dementia strategy, the UK is shifting towards an integrated policy approach. According to Alzheimer’s Disease International’s latest From Plan to Impact publication, the UK is currently at Stage 2D. This indicates that dementia is under consideration for inclusion within a “grouped health plan”, meaning it will likely be integrated into a broader framework encompassing related areas such as older persons’ health, neurology, or non-communicable diseases.

Significant efforts are focused on blood-based biomarker research to create less invasive, cheaper, and more accessible diagnostic tests for dementia. The Blood Biomarker Challenge is funding studies like READ-OUT at the University of Oxford, testing various blood tests for different dementia types, and ADAPT at UCL, focusing on the p-tau217 biomarker for early Alzheimer’s disease diagnosis.

An AI tool developed at the University of Cambridge can predict the progression of Alzheimer’s disease in individuals with early signs of dementia with high accuracy. This tool uses routinely collected cognitive test results and MRI scans to determine if and how quickly someone will progress to Alzheimer’s disease, outperforming current clinical methods.

iLoF, a UK company, is developing Optomics technology, which uses photonics and AI to analyse blood-based biomarkers for next-generation Alzheimer’s disease screening. This non-invasive and cost-effective method aims to improve early detection.

AINOSTICS Limited, another UK company, is creating AI-enabled technology to analyse brain scans to predict and characterize dementia risk by extracting detailed micro-structural information and comparing it to healthy populations.

Cumulus Neuroscience Limited has developed a platform to collect longitudinal, objective real-world data for neurodegenerative disease studies, including Alzheimer’s disease. This platform uses a medical-grade EEG headset and tablet-based cognitive assessments for continuous monitoring at home and in clinics.

Researchers at Lancaster University have pioneered a new method to detect Alzheimer’s disease by analysing the coordination between brain oxygenation, neuronal function, heart rate, and respiration. Their analysis of these physiological rhythms revealed a higher respiration rate in individuals with Alzheimer’s disease, suggesting potential links to brain inflammation and offering a simple, non-invasive diagnostic approach.

Scientists at the University of Exeter Medical School are using advanced “long-read” sequencing technology to study gene expression in the brain in detail, identifying new versions of genes associated with tau protein accumulation in Alzheimer’s disease. This research has uncovered specific gene isoforms linked to tau and has made their analysis tools publicly available.

One study in the UK has identified a crucial interaction between Amyloid Precursor Protein (APP) and talin, a synaptic protein, suggesting this interaction is vital for the mechanical integrity of synapses and memory. The research proposes that APP misprocessing in Alzheimer’s disease disrupts this pathway, leading to synaptic degeneration and memory loss, and suggests repurposing cancer drugs that stabilize cell adhesions as a potential treatment.